Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.50 |
| ▸ | LMNA | P02545 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554259 | 0.90 | ALDH1A1 (0.60) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL1553328 | 0.89 | ALDH1A1 (0.48) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL1553883 | 0.89 | ALDH1A1 (0.55) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL1554495 | 0.89 | PTPN1 (0.52) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL4252376 | 0.87 | ALDH1A1 (0.53) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL1554744 | 0.85 | HSD17B10 (0.47) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL1554657 | 0.85 | ALDH1A1 (0.49) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL1554599 | 0.85 | PRKCZ (0.47) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL4757822 | 0.85 | ALDH1A1 (0.47) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL1553441 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNAHPGDSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383463-B1 | FUSED THIOPHENE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF CHRONIC PAIN | KING PHARMACEUTICALS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1383463-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | KING PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7449490-B2 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7101905-B2 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060183921-A1 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-08-17 | — | — | US | disclosed |
| EP-1383463-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | King Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002083083-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | KING PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183921-A1 | Pharmaceutically active compounds and methods of use | TRPV1, TPMT, ACHE | ALDH1A1 1591/4885LMNA 4578/4885HPGD 726/4885 |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | TRPV1, TPMT, ACHE | ALDH1A1 1591/4885LMNA 4578/4885HPGD 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.